Skip to main content
. 2021 Jul 26;14:3941–3949. doi: 10.2147/IJGM.S313486

Figure 1.

Figure 1

Symptom prevalence (%) for COVID-19-positive participants by self-reported use of medication for autoimmune disease.

Notes: (A) Prevalence (%) of any symptom; taking medication for autoimmune disease at enrollment. (B) Prevalence (%) of any symptom; not taking medication for autoimmune disease at enrollment. (C) Prevalence (%) of moderate or severe symptoms; taking medication for autoimmune disease at enrollment. (D) Prevalence (%) of moderate or severe symptoms; not taking medication for autoimmune disease at enrollment. Data cut as of March 1, 2021. Sample size: taking medication for autoimmune disease: day 0: n=70; day 7: n=59;day 14: n=54; day 21: n=45; day 30: n=42. Not taking medication for autoimmune disease: day 0: n=1,448; day 7: n=1,199; day 14: n=1,043; day 21: n=945; day 30: n=951. Survey windows: 0=enrollment; 7=days 3–10; 14=days 11–17; 21=days 18–24; 30=days 25–45.